Mariangela Allocca, Gaia Catalano, Edoardo V Savarino, María Chaparro, Asaf Levartovsky, George Michalopoulos, Nikos Viazis, Fotis S Fousekis, Andreas Psistakis, Daniele Noviello, Catarina Neto do Nascimento, Benedicte Caron, Vassiliki Kitsou, Giorgos Bamias, María José García, Eirini Zacharopoulou, Kalliopi Foteinogiannopoulou, Ferdinando D'Amico, Ioannis Koutroubakis, Pierre Ellul, Maria Tzouvala, Laurent Peyrin-Biroulet, Joana Torres, Flavio Caprioli, Konstantinos Karmiris, Angeliki Theodoropoulou, Konstantinos H Katsanos, Dimitrios K Christodoulou, Gerassimos J Mantzaris, Uri Kopylov, Javier P Gisbert, Silvio Danese, Fernando Magro, Fornari Carla, Gionata Fiorino
BACKGROUND: Ustekinumab and tofacitinib have recently been approved for the management of moderate to severe ulcerative colitis (UC). However, there is no evidence on how they should be positioned in the therapeutic algorithm. The aim of this study was to compare tofacitinib and ustekinumab as third-line therapies in UC patients in whom anti-TNF and vedolizumab had failed. METHODS: This was a multicenter retrospective observational study. The primary outcome was disease progression, defined as the need for steroids, therapy escalation, UC-related hospitalization and/or surgery...
February 28, 2024: United European Gastroenterology Journal